Introduction
Multiple biological events have been demonstrated to be under control of receptor tyrosine kinases (RTKs) during the human cancer development. Activated RTKs utilize adaptor molecules including Shc family and Grb2 proteins to trigger intracellular signaling pathways, such as the Ras-MAPK pathway and the phosphoinositide 3-kinase (PI3K)-Akt pathway. These adaptor molecules are, therefore, closely associated with regulation of cell proliferation, differentiation, survival and oncogenesis (Asai et al., 1996; Collins et al., 1999; Goga et al., 1995; Gotoh et al., 1996) . Shc proteins are composed of an N-terminal phosphotyrosine binding (PTB) domain, a central glycine/prolinerich region (CH1) and a C-terminal Src homology 2 (SH2) domain (Pelicci et al., 1992; van der Geer et al., 1995) . The binding affinity of the PTB domain and the SH2 domain to phosphotyrosine residues of RTKs transfers Shc proteins toward the cellular membrane upon ligand stimulation (Laminet et al., 1996; Pawson et al., 2001; van der Geer et al., 1996) . Shc proteins phosphorylated at tyrosine residues by activated RTKs subsequently recruit SH2-containing adaptor molecules such as Grb2 (Gotoh et al., 1996; van der Geer et al., 1996) .
Shc family proteins consist of ShcA (Shc), ShcB (Sli/ Sck) and ShcC (Rai/N-Shc) which are encoded by three independent genes (Nakamura et al., 1996a; O'Bryan et al., 1996b; Pelicci et al., 1996) . ShcA is expressed ubiquitously in most of the organs except the adult neural system and has three protein isoforms, p46
ShcA , p52
ShcA and p66 ShcA . During embryogenesis, the ShcA protein plays the first critical role in the cardiovascular system at E9 (Lai and Pawson, 2000) . In the neural system, the ShcA mRNA was detected in the ventricular zone of day 12.5 mouse embryo and peripheral nerves of day 19 rat embryo (Conti et al., 1997; Nakamura et al., 1998) . In the case of ShcB, mRNA expression was detected in wide range of organs while protein expression is rather specific to brain and spinal cord with a trace amount of expression in lung, heart and stomach (Sakai et al., 2000) . Protein expression of ShcC (p52 ShcC and p67
ShcC isoforms) was restricted to the neural system in mouse O'Bryan et al., 1996b; Pelicci et al., 1996) . Expression of ShcC is low in the embryonic brain, while remarkably elevates after delivery (Sakai et al., 2000) . ShcB expression remains at the same level during pre-and postnatal development. On the other hand, ShcA expression is most significant in the prenatal period with sudden decrease after birth (Conti et al., 1997) . Mice lacking both ShcB and ShcC exhibit a significant loss of neurons within the superior cervical ganglia suggesting redundant roles of ShcB and ShcC in the trkA signaling (Sakai et al., 2000) . Functional analysis of the ShcB/ShcC on the neuronal signaling pathway indicated that these proteins in neuronal cells potentially regulate EGF or NGF signaling in a similar fashion to ShcA O'Bryan et al., 1996a ).
In the current study, we examined involvement of each Shc family protein in human neuroblastoma and other tumor cells of neural origin, by checking expression and tyrosine phosphorylation of these proteins. Neuroblastoma is the most common pediatric solid tumor and its origin is the sympathoadrenal lineage of the neural crest. N-myc gene amplification is recognized as one of the most important negative prognostic factors of neuroblastoma. Recent studies indicate that tyrosine kinase receptors, such as TRK family might be closely involved in the oncogenesis of neuroblastomas (Layfield et al., 1995) , but involvement of ShcB or ShcC proteins in oncogenic signals from RTKs of neural tumor cells has not been reported.
As results, expression and tyrosine phosphorylation of Shc family proteins, especially ShcC, were observed in most of neuroblastoma cell lines. Phosphoproteins associated with ShcC were immuno-affinity purified in order to identify components of ShcC signaling complex including the activated RTK(s) responsible for ShcC phosphorylation. The mass-spectrometry analysis revealed that a known RTK, anaplastic lymphoma kinase (ALK) is a major 200 kD component of ShcC associated phosphoproteins. Further genetic and biochemical analyses were performed to elucidate the molecular mechanism of ALK activation and roles of ALK-ShcC complex in the biological characteristics of neuroblastoma.
Results

Expression and tyrosine phosphorylation of Shc family proteins in neuroblastoma and other tumor cell lines of neural origin
To examine specific expression and phosphorylation of each Shc family protein, specific antibodies against CH1 domains of each Shc protein were prepared which show significant diversity among Shc family members. Specificities of anti-ShcB and anti-ShcC antibodies were previously checked using samples from ShcB/ ShcC knockout mice (Sakai et al., 2000) . An anti-ShcA specific antiserum was raised for the current study as described in materials and methods. Twelve neuroblastoma cell lines, four other neuronal tumor cell lines, neuroepithelioma, glioblastoma and melanoma, and three non-neuronal tumor cell lines were analysed in this study (Table 1) . ShcC expression was detectable in 10 out of 12 neuroblastoma cell lines, including eight cell lines with tyrosine phosphorylation of ShcC (Table  1) . The proportion of the expression level of p52
ShcC to that of p67
ShcC was mostly conserved in each cell line. Some of these cell lines, such as NB-39-nu and Nagai cells, showed marked tyrosine phosphorylation of ShcC, in spite of rather low expression level of ShcC ( Figure 1a ). Besides neuroblastoma cell lines, tyrosine phosphorylated ShcC was observed in two of three neuronal tumor cell lines which expressed ShcC. A few distinct phosphoproteins were associated with hyperphosphorylated ShcC-containing cells, with approximate molecular weights of 135 kD, 170 kD and 200 kD in NB-39-nu and Nagai cells, 110 kD and 130 kD in TNB1 cells and 80 kD, 100 kD and 120 kD in SK-N-MC cells, respectively ( Figure 1a and data not shown).
Trace level of tyrosine phosphorylation of ShcC was detected in VMRC-RCZ, a human renal cancer cell line, suggesting that the neuro-specificity of ShcC might be lost in undifferentiated solid tumor cells (data not shown). No expression of ShcC was recognized in tumor cell lines of the hematopoietic lineage, such as THP-1, K562 and HELL, most of which had considerable expression of p52 ShcA (data not shown).
ShcA was also expressed in most of neuroblastoma cell lines analysed ( Figure 1b and Table 1 ). None of the Shc family proteins were detected in the adult brain using the same antibody, showing that this antibody is not cross-reacting with ShcB or ShcC (Figure 1b) . The p46 ShcA isoform could not be constantly separated from the immunoglobulin heavy chain after immuno- ShcA was detectable in three out of six neuroblastoma cell lines in our analysis. There was obvious difference between the pattern of tyrosine phosphorylation of ShcA and ShcC among these cell lines. For example, the tyrosine phosphorylation of ShcC but not ShcA was detected in SK-N-MC and SK-N-SH and on the contrary, ShcA phosphorylation, not ShcC, was mainly detected in YT-nu. The expression level of ShcB was quite low compared with that in the brain and its phosphorylation was undetectable in any of neuronal cell lines examined (Figure 1b, lower panel) .
Expression of tyrosine-phosphorylated ShcC in neuroblastoma tissues
Tissue samples of neuroblastoma were mainly derived from children in various stages and prognosis (as shown in Table 2 ). ShcC was significantly expressed in all of the four tumor samples, and tyrosine phosphorylation of ShcC was visible in three tumor samples (Figure 1c) . Notably, tumor samples of patients of the advanced clinical stage, Pt.2 and Pt.3, showed elevated tyrosine phosphorylation of ShcC comparing with other patients. A few ShcC-associated phosphoproteins, such as 75 and 90 kD phosphoproteins were observed. In these four tumors, we could detect ShcA expression at different levels, but we failed to show tyrosine phosphorylation of ShcA (data not shown). Our mouse ShcB antibody could detect faint bands of p68 ShcB in some of the human tissues (Figure 1d ), which were not tyrosine phosphorylated.
Analysis of ShcC-binding phosphoproteins in NB-39-nu and Nagai cells NB-39-nu and Nagai cells were brought to further analysis because they showed the most outstanding tyrosine phosphorylation of ShcC and similar consistent species of phosphotyrosine-containing proteins to each other (Figure 2a ; left panel). Their molecular Several antibodies against proteins which are known to be associated with Shc, such as TRK, EGFR, Nmethyl-D aspartate (NMDA) receptor e2, SHIP, ErbB-2 and Ret, failed to stain these ShcC-associated phosphoproteins, indicating that these 135 -200 kD phosphoproteins are different from these molecules.
Immunoaffinity purification of ShcC-binding phosphoproteins
To identify the phosphoproteins associated with ShcC, we performed two-step immunoaffinity purification using the anti-ShcC antibody and the anti-phosphotyrosine antibody, 4G10. As a first step, the lysate of NB-39-nu cells was coupled to the anti-ShcC antibody column, eluted by the 8 M urea solution and then renatured. This denaturation-renaturation process was required to expose phosphotyrosine residues out of complexed proteins for the next affinity purification step (Sakai et al., 1994) . The sample was then applied to anti-phosphotyrosine antibody column and phosphotyrosine-containing proteins were selectively eluted by 0.1 M phenylphosphate, an analog of phosphotyrosine. The specificity and the efficiency for each ShcC-binding phosphoproteins semi-purified from NB-39-nu cells by two-step immunoaffinity purification (as described in Materials and methods). The sample indicated in the figure was obtained from 1.5610 9 NB-39-nu cells. Aliquots were collected into one and 0.1 volume of all was subjected to silver staining to estimate the quantity. Molecular mass analyses of Lys-C fragments were performed mainly for the bands shown by arrowheads. Positions of molecular mass markers (kD) are shown to the left purification step were monitored by immunoblotting using 4G10 and the silver staining. For the purpose of mass-spectrometry analysis, the cell lysate of 5610 9 NB-39-nu cells at confluency was collected, purified through the procedure above, concentrated by lyophilization and precipitated by 10% trichloroacetate. Finally, yields of semi-purified proteins which correspond to the 135 -200 kD phosphotyrosine-containing bands were estimated as 50 -100 ng by silver staining of the aliquot (Figure 2b ).
Identification of ShcC-binding phosphoproteins
To perform molecular mass analyses of Lys-C fragments, the sample was separated by SDS -PAGE and blotted onto a PVDF membrane, then proteins on the membrane were visualized by the Coomassie staining. We analysed nine visible bands between 70 kD and 200 kD by the MALDI-TOF MS system. After Achrobacter protease I (a Lys-C) digestion, p200 contained 13 peptide fragments which have exact molecular weights of fragments expected from human anaplastic lymphoma kinase (ALK) (arrow a in Figure  2b ). Similar pattern of fragments was detected from bands of 135 and 170 kD, although amounts of the proteins were enough to be fully identified (arrows c and b in Figure 2b ). Besides them, the bands of 70 kD and 90 kD were revealed to be FUS and EWS respectively, both of which belong to RNA-binding proteins (arrows e and d in Figure 2b ). Biological significance of these two molecules is currently under investigation.
To confirm the complex formation between ShcC and ALK proteins, lysates from NB-39-nu and Nagai cells immunoprecipitated with either ShcC or ALK were analysed using anti-ALK antibodies. Multiple proteins of 135, 170 and 200 kD were detected by antibodies against C-terminal and cytoplasmic portions of ALK (Figure 3a and data not shown), indicating that the 135 -200 kD ShcC-binding proteins were, as we expected, ALK and closely related molecules, such as splice variants or degradated products. In addition to that, the 200 kD allele of the ALK protein was also recognized with the anti-ALK antibody against Nterminal portion (data not shown).
In vitro pull-down assay using SH2 and PTB domains of ShcC protein fused with GST (glutathion Stransferase) demonstrated that only the PTB domain of ShcC could bring down ALK (Figure 3b We tried to use pleiotrophin (PTN), a recently identified ligand of ALK (Stoica et al., 2001) , to investigate whether tyrosine phosphorylation of the ALK in these cells was induced by ligand-dependent or ligand-independent manner. Although various concentrations of PTN were tested in several different cell lines, we could not find any evidence that PTN functions as a ligand of ALK in neuronal cells (data not shown).
Since the tyrosine phosphorylation of ALK and ShcC was constant even after 24 h starvation in NB-39-nu and Nagai cells, we next investigated the effect of constitutive activation of ALK on the other growth factor pathways. In these cells, the EGF stimulation did not affect on the phosphorylation level of ShcC any further (Figure 5a ), while prominently increased tyrosine phosphorylation of ShcC in YT-nu or T98G cells which presented no overexpression of ALK. Upon the ligand stimulation, the phosphorylated EGF receptor coprecipitated with ShcC was clearly visible at 180 kD in most of neural tumor cell lines, which appears much less in NB-39-nu and Nagai cells (Figure 5a ShcC phosphorylation in any of the four cell lines indicating the TrkA-ShcC pathway might not have the main contribution to the activation of MAPKs in these tumor cell lines. These observations suggest that constitutive activation of the ALK kinase and formation of the stable ALK-ShcC complex might cause these cells to acquire unresponsiveness to the regulation by other growth factors.
Other docking molecules, IRS-1 and PLC g are reported to be associated with ALK when it is activated as a fusion form of NPM-ALK (Iwahara et al., 1997; Morris et al., 1997) . Trace levels of 200 kD phosphoproteins, possible ALK, were immunoprecipitated by IRS-1 in Nagai cells (Figure 6a ) and by PLC g in Nagai and NB-39-nu cells (Figure 6b lanes 1 and 3) suggesting formation of ALK-IRS-1 and ALK-PLC g complexes in these cell lines. However, phosphorylation levels of IRS-1 and PLC g were similar or even lower than in other neuronal tumor cells (Figure 6 lanes 2, 4, 6 and 8).
Overexpression and phosphorylation of ALK are associated with gene amplifications
As gene amplification could be one of the causes of overexpression of the gene products, we then checked the copy number of the ALK gene by Southern blot analysis using the probe for the juxtamembrane segment of the ALK cDNA. The ALK gene was markedly amplified in NB-39-nu and Nagai compared with other six cell lines, while the control ShcC gene remained unchanged (Figure 7 ). The N-myc locus (2p24) is frequently amplified in neuroblastoma and located rather close to that of ALK (2p23). N-myc gene was amplified in NB-39-nu, Nagai and NB-1 cells (Figure 7 and Ikeda et al., 1990) . There were other cell lines, such as YT-nu, which showed amplification of N-myc with apparently single copy of ALK. Although numbers of the samples are not enough, ALK gene amplification might occur in some cases of N-myc amplification. From these results, it was shown that increased copy number of the ALK gene resulted in overexpression of the ALK protein in these neuroblastoma cells.
Discussion
As previously reported, the ShcA protein is constitutively phosphorylated in more than half of human tumors in association with activation of various tyrosine kinases (Pelicci et al., 1995) . However, no investigation about expression and phosphorylation of ShcB/ShcC in tumor cells has been published so far. We presented here expression and tyrosine phosphorylation of Shc family protein, especially ShcC, in human neuroblastoma and other neuronal tumor cells. Tyrosine phosphorylation of ShcC was observed in most of neuroblastoma cells, suggesting that ShcC might play important roles during neuronal tumorigenesis caused by perturbation of particular RTK signals in a tissue specific manner. Extent of tyrosine phosphorylation of ShcC in neuroblastoma tissues which express ShcC, demonstrates possible correlation with the clinical stage and prognosis of neuroblastoma patients. In the case of human breast cancers, overexpression and constitutive activation of ErbB-2 protein which result in recruitment of Grb2 and Shc to the membrane are correlating with poor clinical prognosis (Dankort et al., 2001) . Tyrosine phosphorylation of ShcC might represent aberrant oncogenic signals initiating from activated RTKs caused by genetic alterations such as mutations and amplifications. This is also the first report to show that the unfused form of ALK protein is constitutively activated in tumor cells by overexpression, although there are recent reports showing that expression of the ALK mRNA and protein in a wide range of human neuroblastoma cell lines and tissues (Lamant et al., 2000; Passoni et al., 2002) . ALK is known to acquire transforming ability as a fusion protein, NPM -ALK, formed by the t(2;5) chromosomal rearrangement in non-Hodgkin's lymphoma (Bischof et al., 1997; Fujimoto et al., 1996; Kuefer et al., 1997; Morris et al., 1994) . In NPM -ALK, the cytoplasmic catalytic domain of ALK is conserved, and the N-terminal NPM sequence serves oligomerization motif which leads to constitutive activation of NPM -ALK and the cellular transformation (Bischof et al., 1997) . Fragments of about 1.9 kb, 2.8 kb and 4.0 kb were detected using the 32 P-labeled probe prepared as described in Materials and methods. The ALK gene was markedly amplified in the genome DNA of NB-39-nu and Nagai cells comparing with samples of other cell lines which contained equal quantity of total DNA. Similarly, amplification of the N-myc gene was recognized in the samples of 10 mg of DNA digested with EcoRI derived from YT-nu, NB-39-nu and Nagai cells. As a control for the amounts of DNA, the same filter was re-hybridized with the probe for ShcC Fujimoto et al. (1996) indicated that cytoplasmic signals originating from the N-terminal NPM sequence is essential for the transforming activity of the fusion protein in NIH3T3 cells. The ALK protein we identified here contains both N-terminal and Cterminal portions as revealed by specific antibodies and shows an apparent molecular weight close to 200 kD, suggesting no massive deletion or rearrangement occurred in the ALK protein. We performed the RT -PCR analysis using 14 primer pairs covering the full length of human ALK cDNA (Iwahara et al., 1997; Morris et al., 1997) , each giving an about 500-bp fragment (data not shown). The analysis revealed a small in-frame deletion of the cDNA (encoding a sequence from His-224 to Gly-318), which corresponded to a part of the extracellular domain of ALK in NB-39-nu, Nagai and YT-nu cells. This deletion was not detected by Southern blot analysis, suggesting the deletion found in the cDNAs of the three cell lines could be caused during maturation of mRNA. The fact that the deletion was also found in YT-nu cells indicates that it is not an activating mutation for the ALK kinase.
Several different mechanisms causing oncogenic activation of RTKs have been reported, such as gain of function mutations or small deletions, genomic rearrangements and gene amplification (reviewed in reference: Blume-Jensen and Hunter, 2001). Since there was no apparent activating mutation of the ALK protein in our study, it was concluded that gene amplification of ALK is principally responsible for constitutive activation of the ALK kinase in NB-39-nu and Nagai cells. As increased local concentration of receptor tyrosine kinases might lead to constitutive activation of the kinase, gene amplification can be the direct trigger of RTK activation as reported in EGFR and Neu/ErbB2 (Andrechek et al., 2000) , but this is the first observation of amplification of the ALK gene. In addition to the ALK gene, the N-myc gene amplification had been recognized in NB-39-nu, Nagai cells and also in NB-1 cells. Both ALK and N-myc are known to be at the distal short arm of chromosome 2 in the vicinity (2p23 and 2p24, respectively). The process of N-myc gene amplification frequently involves coamplification of extensive regions of the DNA flanking the N-myc gene. The size of the N-myc amplicons varies among cell lines to over 1 Mb, including approximately 7 kb of the N-myc gene (Akiyama et al., 1994; Hiemstra et al., 1994) . Additionally, contribution of genes co-amplified with N-myc to cancer progression was also proposed (George et al., 1996; Wimmer et al., 1999) . Since no information about range of amplification or exact distance between ALK and N-myc loci was obtained, we could not conclude that a single amplicon contains both of these genes. It is possible, however, that the stage in which both ALK and N-myc are amplified and overexpressed might give additional effects on malignant phenotype of NB-39-nu, Nagai and NB-1 cells.
The phosphorylated ALK expressed in NB-39-nu and Nagai cells binds both ShcA and ShcC. It is suspected that constitutively phosphorylated ShcA and ShcC might have some redundant and overlapping roles as frequently seen in families of signaling molecules. On the contrary, they could have individual unique functions through the binding to the ALK proteins. As recently reported, ShcA and ShcC play different roles in survival and differentiation of neural stem/progenitor cells. ShcC positively affects their viability and neuronal differentiation through PI3K and MAPK pathways (Conti et al., 2001) . Marked elevation of ShcA mRNA was also reported in the post-injured rat hypoglossal motoneurons, whereas ShcC mRNA was down-regulated (Tanabe et al., 1998) .
Substrate specificity of each tyrosine kinase is known to be closely associated with its unique biological activities. ShcC is shown to be a potent substrate of the ALK kinase by in vitro kinase assay. Therefore, it is estimated that activation of the ALK kinase is responsible for the hyperphosphorylation of ShcC in NB-39-nu and Nagai cells. As reported in NPM -ALK, the C-terminal portion of ALK contains two potential PTB binding sites known as NPXY motifs (NPNY, aa1093 -1096 and NPTY, aa1504 -1507 (Iwahara et al., 1997; Morris et al., 1997) . ShcA was shown to bind phosphorylated NPTY, whereas IRS-1 binds NPNY in NIH3T3 cells transfected with NPM -ALK (Fujimoto et al., 1996) . In our study, ALK did not form any stable complexes constitutively with other docking molecules, IRS-1 and PLC g, which were phosphorylated at lower levels than in some of other neuronal tumor cells. The result indicates that the activated ALK might phosphorylate ShcC rather selectively and perturbs downstream signals, such as Ras-MAPK in neuroblastoma cells. We could not find the example of activation of the ALK protein in neuroblastoma tissues due to the limited number of samples; it is natural to think that the ALK gene, just like N-myc, is amplified in some of progressed neuroblastomas, adding more malignant phenotype to the tumors through activation of the ALK-ShcC pathway.
Materials and methods
Cell culture and tissue samples
Cell lines of Neuroblastomas; NB-39-nu, YT-nu (Ishikawa, 1977; Kuga et al., 1975) , SK-N-DZ (Sugimoto et al., 1984) and Nagai (Ishikawa et al., 1979) Table 2 . These cells were cultured in their respective medium indicated by each developer with 10% fetal calf serum (Gibco-BRL or Sigma). Cell culture was performed at 378C and 5% CO 2 .
Four frozen neuroblastoma tissues were provided by the Department of Pediatrics, University of Kitasato. Nude mouse tumors were generated by injecting 5610 6 NB39-nu, Nagai, YT-nu or SK-N-SH cells to subcutaneous tissues of each mouse.
Preparation of anti-ShcA, ShcB and ShcC specific antibodies and anti-ALK antibody
The polyclonal antibodies against the CH1 domains of mouse ShcB (amino acid 310-477) and ShcC (amino acid 306 -371) were prepared as described (Sakai et al., 2000) . Anti-ShcA (amino acid 271 -332) antibody and anti-ALK antibody (ALK(GST)) which was against the cytoplasmic portion (amino acid 1379 -1524) of human ALK were raised in rabbits and affinity-purified. An antibody against N-terminal portion of human ALK (N-19) and an antibody against Cterminal portion of human ALK (C-19) were purchased from Santa Cruz Biochemistry. An anti-phosphotyrosine antibody (4G10) was obtained from UBI. Anti-p44/42 MAPK and anti-phospho-p44/42 MAPK antibodies were purchased from BioLabs. Anti-IRS-1 and anti-PLC g1 antibodies were purchased from Santa Cruz Biotechnology. As secondary antibodies horseradish peroxidase (HRP) conjugated antirabbit and anti-mouse IgG. Protein A (Amersham) and HRP-conjugated anti-goat IgG (ICN Pharmaceuticals) were used.
Cell stimulation, immunoprecipitation and immunoblotting
Cell stimulation analysis was performed with epidermal growth factor (EGF; wako) (100 ng/ml) or nerve growth factor (NGF; Wako) (100 ng/ml). Before stimulating cells were starved for 18 h and treated for 5 min with indicated concentrations. Then, cells were rinsed with ice-cold PBS and lysed in PLC-lysis buffer (Rozakis-Adcock et al., 1993) . Lysates containing 100 mg of total proteins per lane were applied to gels for immunoblotting, while 500 -1000 mg of total proteins were mixed with 1 -2 mg of each antibody for immunoprecipitation. The samples containing immunecomplex were incubated at 48C in rotating shaker with Protein A or G-Sepharose TM -4B (Amersham Pharmacia) beads for 1 -3 h, and then the beads were washed with PLClysis buffer. After boiling the lysates or immunoprecipitated materials in SDS sample buffer (2% SDS, 0.1 M Tris-HCl, pH 6, 10% glycerol, 0.01% bromophenol blue, 0.1 M dithiothreitol), each sample was resolved by SDS -PAGE and transferred onto polyvinylidene difluoride membrane filters (Immobilon, Millipore). The membranes were blocked with 5% bovine serum albumin or skim-milk and proved with the appropriate diluted antibodies at room temperature. The blots were treated with horseradish peroxidase-conjugated secondary antibodies and visualized using chemicalluminescence (Renaissance, NEN TM + Life Science Products).
In vitro pull down assays cDNAs encoding the SH2 (amino acid 29 -189) or PTB (amino acid 377 -474) domain of mouse ShcC were subcloned into the pGEX-4T2 vectors and expressed as GST fusion proteins in E coli after induction by isopropyl-b-D-thiogalactopyranoside (IPTG). After centrifugion of bacterial culture, the pellets were lysed in L buffer (50 mM Tris-HCl, pH 7.4, 25% sucrose, 5 mM MgCl 2 , 0.5% Nonidet P-40) by sonication. These proteins were purified on glutathione-agarose beads (Sigma) and dialyzed with 0.1 M borate buffer (pH 8.5, 0.5 M NaCl). After coupling with CNBr-activated Sepharose 4B (Pharmacia), proteins were incubated in 50 mM Tris (pH 7.4), 150 mM NaCl, 0.05% sodium azaide. Equal amounts of each GST fusion coupling sepharose were incubated with equivalent amounts of lysates from NB-39-nu or Nagai cells at 48C for 2 h. These mixes were washed with PLC-lysis buffer four times and resuspended in SDS sample buffer. Then immunoblotting was performed as described.
Immunoaffinity purification of ShcC-binding phosphoproteins
Immunoaffinity purification of phosphoproteins was basically performed as described (Sakai et al., 1994) . Briefly, the antiShcC antibody-Sepharose gel and 4G10-Sepharose gel were prepared using CNBr-activated Sepharose 4B (Amersham). NB-39-nu cells lysed in PLC-lysis buffer were coupled with 1/ 20 volume of aShcC-Sepharose gel for 6 h at 48C, and washed with 10 volumes of PLC-lysis buffer. Proteins eluted from the first immunoaffinity column using 8 M urea buffer (8 M urea, 1% Triton X-100, 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM Na 3 VO 4 ) were renatured by dialysis against a solution of 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM Na 3 VO 4 and 1 mM phenylmethylsulfonyl fluoride, and then incubated with 0.1 volume of the 4G10-Sepharose gel and rotated slowly for 5 h at 48C. Beads were washed with PLClysis buffer and 0.1% heptylglucoside, 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, and eluted by 0.1 M phenylphosphate buffer (0.1 M phenylphosphate, 0.1% heptylglucoside, 10 mM Tris-HCl, pH 7.4, 150 mM NaCl). Fractions containing antiShcC binding phosphoproteins were collected, concentrated and precipitated with 10% trichloroacetate.
Identification of proteins by peptide mass mapping
Purified proteins separated by gel electrophoresis were blotted onto a PVDF membrane (ProBlott, Applied Biosystems) and then stained with Coomassie Stain Solution (Bio-Rad) to recognize the appropriate band to cut out for peptide mass mapping. The immobilized proteins were reduced, S-carboxymethylated, and digested in situ with Achromobacter protease I (a Lys-C) (Iwamatsu, 1992; Iwamatsu and Yoshida-Kubomura, 1996) . Molecular mass analyses of Lys-C fragments were performed by Matrix-assisted Laser Desorption/Ionization time-of-flight (MALDI-TOF) mass spectrometry using a PerSeptive Biosystem Voyager-DE/RP. Identification of proteins was carried out by comparison between the molecular weights determined by MALDI-TOF/ MS and theoretical peptide masses from the proteins registered in NCBInr (9.19.2001) (Ole et al., 1996) .
In vitro tyrosine kinase assays
Cell lysates containing 1 mg of proteins were mixed with 1 mg of aALK(GST) or anti-ShcC antibody and incubated for 1 h on ice. Samples were rotated with Protein G-SepharoseTM-4B (Amersham Pharmacia) for 1 h at 48C, then the beads were washed three times in the PLC-lysis buffer and three times in kinase buffer (50 mM Tris HCl, pH 7.4, 50 mM NaCl, 10 mM MgCl 2 ,10 mM MnCl 2 ). The kinase reaction was performed in 30 ml of kinase buffer with 5 mCi of [g 32 P]ATP (Amersham) at room temperature for 30 min (without exogenous substrate) or 378C for 10 min (with exogenous substrate). Twenty mg of poly-Glu/Tyr (4 : 1) (Sigma) was used as a exogenous substrate for each sample (Sakai et al., 1997) . Samples were boiled in the SDS sample buffer and separated by polyacrylamide gel. The gels were dried and exposed to an X-ray film and subjected to autoradiography.
DNA extraction and Southern blotting
Genomic DNAs were obtained from cultured cells as described by the procedure of Perucho et al. (1981) . Samples of 10 mg of DNA digested with respective enzymes were electrophoresed in 0.8% agarose gel and transferred to nitrocellulose filters by the method first described by Southern (1975) . The probes for detecting the ALK genome were prepared using the RT -PCR product (843 bp fragment) encoded the juxtamembrane segment of the ALK cDNA (3938 -4781) . The probe for the N-myc gene was prepared from the 2 kb BglII-EcoRI fragment of the genomic clone, pN-myc2238, kindly provided by Dr Y Taya, which was to detect 3.8 kb of the genomic N-myc DNA digested by EcoRI (Kohl et al., 1986; Stanton et al., 1986) . As a control we used the probe for detecting ShcC gene, that was obtained by digesting pCMV1-T7N-Shc, human ShcC cDNA, kindly provided by Nakamura et al. (1996b) . The probe contained 1.1 kb of cDNA sequence, corresponding to PTB and CH1 domains of the human ShcC protein.
